TNDM

Tandem Diabetes Care, Inc. (TNDM) | Rumor.io

Tandem Diabetes Care

TNDM

Attention (50-day avg)0%

Attention rank (50-day avg)#1,301

Bullish sentiment (50-day avg)98%

Price to earnings ratio-5.4

Market capitalization1.1B

Earnings per share-0.9

Dividend yield (TTM)—

Revenue (annual)1B

Net income (annual)-204.7M

Social

What share of all stock conversation is about TNDM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0.01% +0.01	0% +0	0% 0

Sep 24

A large trade of $1.2M was made in Tandem Diabetes Care, with the investor betting on the stock's potential revival due to upcoming FDA news and 2027 projections.
The company's stock price has declined significantly, from $24 to $15.2 in 6 weeks, with some speculating that this might be related to a potential Mobi FDA leak.
Tandem Diabetes Care's CEO, John Sheridan, has been criticized for not delivering earnings to shareholders despite earning over $32 million in 2021-2025, with some calling the board of directors "clueless".

Generated by AI

Sentiment

Of the messages about TNDM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +6.67	94.7% +13.16
Bearish	—	—	0% -6.67	5.3% -13.16

Bullish· Feb 21

$TNDM surges to $24.57 +32.67% driven by accelerating product launch momentum, strong earnings beat, and margin expansion.
Tandem Diabetes Care sees robust demand for its insulin pumps, with management expecting further shipment growth in 2026, driving the stock's rally.
The company's technology breakthrough and platform adoption are fueling a massive earnings beat and margin expansion, leading to a major re-rate on growth outlook.

Bearish· Feb 27

The company's gross margin may not be fully resolved due to potential manufacturing issues.
The company's focus on continuous glucose monitoring (CF) may be a major concern, with some investors expecting a decline in its stock price.
The company's stock price has been heavily influenced by short sellers, with some predicting further declines.

Generated by AI

Topics

Of the messages about TNDM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	29.17%	46.42%
Technical Analysis	—	—	70.83%	36.28%
Analysts	—	—	0%	13.67%
Controversies	—	—	0%	0.56%
Earnings	—	—	0%	3.07%
Macro	—	—	0%	0%

Analysts· Feb 25

Tandem Diabetes Care ($TNDM) has seen its price target raised by multiple analysts, including Cowen to $90, Raymond James to $91, and Oppenheimer to $97.
Analysts at Piper Sandler, Stifel Nicolaus, and Craig-Hallum have also increased their price targets for Tandem Diabetes Care, with Piper Sandler at $90, Stifel Nicolaus at $77, and Craig-Hallum at $108.
Raymond James and Piper Sandler have reiterated their "Outperform" and "Buy" ratings for Tandem Diabetes Care, respectively, with price targets of $91 and $90.

Announcements· May 23

Tandem Diabetes Care, Inc. made an announcement, which may not be related to a biotech acquisition.
The announcement may be related to the company's Employee Stock Purchase Plan (ESPP) reaching its cap.
Tandem Diabetes Care, Inc. filed a 8-K form with the SEC on May 23, 2024.

Technical Analysis· Feb 20

$TNDM is showing strong momentum, with bulls in control and a possible upside target.
The stock has a bullish trend, with a strong earnings summary, a "magic" green line pattern, and a bullish iHS pattern on the 1-year chart.
Buyers are consistently supporting price, with relative strength remaining high and a potential continuation of the trend, with a possible pullback to $22 before another leg up.

Generated by AI

Community

Of the messages about TNDM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	31.7%	30.05%	28.66%
Newcomers	0%	68.3%	69.95%	71.34%

Regulars· Feb 20

Tandem Diabetes Care, Inc. ($TNDM) reported a Q4 loss of $0.01 per share, beating the FactSet Consensus by $0.08, and revenues rose 15.1% year/year to $290.4 mln.
The stock's momentum continues to favor the bulls, with a strong trend that has legs, and an upside target is being discussed among regulars.
Tandem Diabetes Care's earnings and 2026 guidance have reshaped the competitive picture for Dexcom ($PODD), with TNDM's report being a net positive for PODD in the near term, but medium-term implications are unclear.

Newcomers· Sep 24

New traders are speculating on $TNDM's potential based on its PayGo projections and FDA lead, with some placing large bets on the stock's revival.
Recent price drops have some users questioning whether there's any news about Mobi FDA approval, and others are simply riding the downtrend.
Traders are criticizing the company's leadership, specifically CEO John Sheridan, for not delivering earnings to shareholders despite his high compensation package.

Generated by AI

News

Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

MILAN, September 28, 2026--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

2d agoYahoo Finance

Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating

Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29, accord

6d agoYahoo Finance

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

6d agoThe Globe and Mail

Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and profit. The share price of US$16.87 comes after a sharp 24.42% decline in the 1 month share price return. However, the 3 month share price return is up 17.64%, and the 1 year total shareholder return of 34.21% indicates momentum that has been building over a longer period, despite weaker 3 and 5...

10d agoYahoo Finance

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

13d agofinance.yahoo.com

Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell (NASDAQ:TNDM)

18d agoSeeking Alpha

Also Discussed

Investors talking about TNDM also mention

#	Name	Attention
1	Insulet CorporationPODD	0%new
2	DexCom Inc.DXCM	0%0
3	Verastem Inc.VSTM	0%0
4	Beta Bionics, Inc. Common StockBBNX	0%0
5	Nemaura Medical Inc.NMRD	0%new
6	Inspire Medical Systems, Inc.INSP	0%new
7	The Baldwin Insurance Group, Inc. Class A Common StockBWIN	0%new
8	Empire State Realty OP, L.P. Series 250 Operating Partnership UnitsFISK	0%0
9	MMMB - MamaMancini's Holdings, Inc.	——
10	Medtronic plcMDT	0%+0

Tandem Diabetes Care, Inc.

Healthcare
Medical Devices

Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology. Tandem Diabetes Care develops and commercializes automated insulin delivery systems designed for people living with insulin-dependent diabetes, with its current product portfolio centered on the t:slim X2 insulin pump and the Tandem Mobi insulin pump. The company’s systems integrate Control-IQ technology and work with compatible continuous glucose monitors to help automate insulin delivery and support day-to-day glucose management. Tandem Diabetes Care also provides related products and services such as infusion sets, cartridges, software updates, data management tools, and mobile applications that support pump users and healthcare providers. Its offerings are used in the United States and in international markets, positioning the company as a specialized player in the broader diabetes care and medical technology sector.

Website

Location

12400 High Bluff Drive

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about TNDM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0.01% +0.01	0% +0	0% 0

Sep 24

A large trade of $1.2M was made in Tandem Diabetes Care, with the investor betting on the stock's potential revival due to upcoming FDA news and 2027 projections.
The company's stock price has declined significantly, from $24 to $15.2 in 6 weeks, with some speculating that this might be related to a potential Mobi FDA leak.
Tandem Diabetes Care's CEO, John Sheridan, has been criticized for not delivering earnings to shareholders despite earning over $32 million in 2021-2025, with some calling the board of directors "clueless".

Generated by AI

Sentiment

Of the messages about TNDM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +6.67	94.7% +13.16
Bearish	—	—	0% -6.67	5.3% -13.16

Bullish· Feb 21

$TNDM surges to $24.57 +32.67% driven by accelerating product launch momentum, strong earnings beat, and margin expansion.
Tandem Diabetes Care sees robust demand for its insulin pumps, with management expecting further shipment growth in 2026, driving the stock's rally.
The company's technology breakthrough and platform adoption are fueling a massive earnings beat and margin expansion, leading to a major re-rate on growth outlook.

Bearish· Feb 27

The company's gross margin may not be fully resolved due to potential manufacturing issues.
The company's focus on continuous glucose monitoring (CF) may be a major concern, with some investors expecting a decline in its stock price.
The company's stock price has been heavily influenced by short sellers, with some predicting further declines.

Generated by AI

Topics

Of the messages about TNDM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	29.17%	46.42%
Technical Analysis	—	—	70.83%	36.28%
Analysts	—	—	0%	13.67%
Controversies	—	—	0%	0.56%
Earnings	—	—	0%	3.07%
Macro	—	—	0%	0%

Analysts· Feb 25

Tandem Diabetes Care ($TNDM) has seen its price target raised by multiple analysts, including Cowen to $90, Raymond James to $91, and Oppenheimer to $97.
Analysts at Piper Sandler, Stifel Nicolaus, and Craig-Hallum have also increased their price targets for Tandem Diabetes Care, with Piper Sandler at $90, Stifel Nicolaus at $77, and Craig-Hallum at $108.
Raymond James and Piper Sandler have reiterated their "Outperform" and "Buy" ratings for Tandem Diabetes Care, respectively, with price targets of $91 and $90.

Announcements· May 23

Tandem Diabetes Care, Inc. made an announcement, which may not be related to a biotech acquisition.
The announcement may be related to the company's Employee Stock Purchase Plan (ESPP) reaching its cap.
Tandem Diabetes Care, Inc. filed a 8-K form with the SEC on May 23, 2024.

Technical Analysis· Feb 20

$TNDM is showing strong momentum, with bulls in control and a possible upside target.
The stock has a bullish trend, with a strong earnings summary, a "magic" green line pattern, and a bullish iHS pattern on the 1-year chart.
Buyers are consistently supporting price, with relative strength remaining high and a potential continuation of the trend, with a possible pullback to $22 before another leg up.

Generated by AI

Community

Of the messages about TNDM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	31.7%	30.05%	28.66%
Newcomers	0%	68.3%	69.95%	71.34%

Regulars· Feb 20

Tandem Diabetes Care, Inc. ($TNDM) reported a Q4 loss of $0.01 per share, beating the FactSet Consensus by $0.08, and revenues rose 15.1% year/year to $290.4 mln.
The stock's momentum continues to favor the bulls, with a strong trend that has legs, and an upside target is being discussed among regulars.
Tandem Diabetes Care's earnings and 2026 guidance have reshaped the competitive picture for Dexcom ($PODD), with TNDM's report being a net positive for PODD in the near term, but medium-term implications are unclear.

Newcomers· Sep 24

New traders are speculating on $TNDM's potential based on its PayGo projections and FDA lead, with some placing large bets on the stock's revival.
Recent price drops have some users questioning whether there's any news about Mobi FDA approval, and others are simply riding the downtrend.
Traders are criticizing the company's leadership, specifically CEO John Sheridan, for not delivering earnings to shareholders despite his high compensation package.

Generated by AI

Tandem Diabetes Care

Social

Sep 24

Bullish· Feb 21

Bearish· Feb 27

Analysts· Feb 25

Announcements· May 23

Technical Analysis· Feb 20

Regulars· Feb 20

Newcomers· Sep 24

Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell (NASDAQ:TNDM)

Also Discussed

Tandem Diabetes Care, Inc.

Company Information

Location

Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating

Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know

Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell (NASDAQ:TNDM)

Also Discussed

Social

Sep 24

Bullish· Feb 21

Bearish· Feb 27

Analysts· Feb 25

Announcements· May 23

Technical Analysis· Feb 20

Regulars· Feb 20

Newcomers· Sep 24